Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether sulindac and VSL#3 - inulin, either combined or alone, are effective in treating or preventing adenoma development in the ileal anal pouch in patients with familial adenomatous polyposis.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00319007
Study type Interventional
Source Radboud University
Contact Pieter Friederich, MD
Phone 00-31-24-3614760
Email P.Friederich@mdl.umcn.nl
Status Recruiting
Phase Phase 2
Start date April 2006
Completion date December 2006

See also
  Status Clinical Trial Phase
Terminated NCT00585312 - Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Completed NCT03095703 - Sirolimus and Familial Adenomatous Polyposis (FAP) Phase 2
Completed NCT03649971 - A Study of Guselkumab in Participants With Familial Adenomatous Polyposis Phase 1
Completed NCT05014360 - A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis Phase 1
Completed NCT01604564 - Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02113202 - Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW Phase 1
Withdrawn NCT03027401 - Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
Terminated NCT00140894 - A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Phase 4
Active, not recruiting NCT01187901 - A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Phase 2
No longer available NCT04948398 - Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis